-
Posted by
Two Blokes Jul 4 -
Filed in
Stock
-
4 views
VANCOUVER, BC / ACCESS Newswire / July 4, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into an agreement with Nucro-Technics Inc. ("Nucro-Technics"), dated July 3, 2025, pursuant to which Nucro-Technics is to conduct a broad range of preclinical studies in support of the Company's lead drug candidate. These specialized lab tests are intended to characterize the drug's behavior in animal and in vitro models, including its bioavailability, biodistribution, pharmacokinetics profile, as well as to assess its safety through regulatory compliant toxicology testing.
